In 2009, the US Food and Drug Administration (FDA) approved EGFR-targeted monoclonal antibody therapy with cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC) along with analysis of KRAS mutation status, which is a predictive biological marker of resistance [6–8]. The gene discussed is KRAS; the disease is metastatic colorectal cancer.